This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Background and Purpose:Whether imaging markers of cerebral small vessel disease on computed tomography (CT-CSVD) relates to early clinical outcomes after intravenous thrombolysis for acute ischemic stroke remains not well understood. Stroke, Volume 56, Issue Suppl_1 , Page AWP6-AWP6, February 1, 2025. 1.02; score 2: OR 0.46, 95%CI 0.26-0.83;
Blackground:Due to the narrow therapeutic time window and strict indications, there are still a large number of patients unable to receive thrombolysis and endovascular therapy, resulting in a poor long-term functional prognosis. AUC range:0.65-0.99).Conclusion:We
Nineteen (68%) MSU patients were diagnosed as stroke, with 17 (61%) confirmed and 2 likely TIA or stroke averted by thrombolysis; 9 were stroke mimics. Median initial NIHSS score was 7 (range 1-22) and 12 (71%) received intravenous thrombolysis with tPA or TNK. IL-6 was independent of lesion volume and NIHSS.
Reperfusion status was assessed by the modified thrombolysis in cerebral infarction score.Results:This study included 137 patients (mean age 69 ± 15, mean NIHSS 14) with LVO stroke who underwent EVT.
BackgroundMicrovascular obstruction (MVO) and intramyocardial hemorrhage (IMH) are well‐established imaging biomarkers of failed myocardial tissue reperfusion in patients with ST‐segment elevation–myocardial infarction treated with percutaneous coronary intervention. Journal of the American Heart Association, Ahead of Print.
Hence, we aimed to study the pro-inflammatory and procoagulant responses post-thrombolysis and their contributory role in clinical outcome.Methods:This is a single-center retrospective study of ALT or TNK treated AIS patients admitted to a comprehensive stroke center over a 3-year period. A p-value of <0.05
For inclusion, patients must have been successfully recanalized by mechanical thrombectomy with or without intravenous thrombolytic and ultimate modified thrombolysis in cerebral infarction (mTICI) score 2B/2C/3. Occurrence of HT was determined from post-interventional imaging, and HT subtype was defined by the ECASS 2 criteria.
Introduction:ACTIMIS (NCT03803007) was a randomized phase 1b/2a clinical trial evaluating glenzocimab, a monoclonal antibody fragment targeting platelet receptor glycoprotein VI in patients with acute ischemic stroke treated by thrombolysis.
We aim to assess whether pretreatment CTP collateral status (CS) parameters can serve as imaging biomarkers for good clinical outcomes prediction in successfully recanalized middle cerebral artery (MCA) DMVOs.Methods:We performed a retrospective analysis of consecutive patients with AIS secondary to primary MCA-DMVOs who were successfully recanalized (..)
Additionally it can serve as an imaging biomarker for the development of adjunctive therapies to mitigate reperfusion injury. Successful recanalization was achieved in 86% and 67% had complete reperfusion, with an overall favorable clinical outcome rate of 54%.
ACTIMIS (NCT03803007) was a randomized phase 1b/2a clinical trial evaluating glenzocimab, a monoclonal antibody fragment targeting platelet receptor glycoprotein VI, versus placebo in patients with acute ischemic stroke treated by thrombolysis alone or associated with mechanical thrombectomy (MT), both subgroups being well balanced.
These patients have worse outcomes: higher mortality, more CHF, higher biomarkers, and worse ejection fractions than the NonSTEMI patients with open arteries. Studies show that 30% of NonSTEMI have an occluded infarct artery at the time of angiography done 24 hours after presentation. This is because of subtle ECG findings. Marti D et al.
We hypothesize serum biomarker analyses during the hyperacute phase can bridge the gap.Methods:This is a single center study of 20 AIS patients&14 age/sex matched controls enrolled from 3/2022-6/2023. DAVID analyses resulted in 22 biomarkers at hospital discharge&35 biomarkers at 90d associated with favorable outcome.
Best Medical Therapy in Acute Ischemic Stroke due to Large VEssel OcclusioN Trial in the Extended Time Window: Raul Nogueira, University of Pittsburgh, Pittsburgh, PA MOST Multi-Arm Optimization of Stroke Thrombolysis Trial: Opeolu Adeoye, Washington University, Saint Louis, MO Thurs.,
What role do risk scores, biomarkers, imaging, and hemodynamics play in decision-making? Should these patients receive anticoagulation alone, or is thrombolysis warranted? How do you predict which intermediate-risk patients will suddenly deteriorate? When should you consider catheter-directed or surgical interventions?
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
40 
Let's personalize your content